The long-term goal of this research is to understand the mechanism(s) of metastasis of prostate cancer to bone. What is the cellular and molecular basis of the osteotropism of prostate cancer in humans? The bone morphogenetic proteins (BMPs) are prime candidates to play a role in prostate metastases and propensity to invade bone. The metastases of prostate to bone is characterized by osteosclerotic lesions and stimulation of osteoblast function. Current work has demonstrated both mRNA and protein for BMPs 4 and 7 in rat and human prostate. Very recently BMP-4 type I receptors were identified in osteoblasts. We will examine the hypothesis that BMP-4 acts on prostate in an autocrine manner via BMP-4 receptors. We will then investigate the hypothesis that metastatic prostate carcinoma over expresses BMP-4 receptor. A novel BMP type I receptor has been identified by PCR-based cloning strategy. We will determine the role of this putative receptor by functional assays. One of us has identified endothelin-1 gene and the protein in osseous metastases in human prostate cancer. Another investigator has identified a novel Bone and Prostate derived Growth Factor-1 (BPGF-1) and confers the metastatic phenotype to human LNCap cells.
The specific aims of this proposal are: 1. Identification and characterization of BMP-4 and BMP-7 in rat and human prostate cancer. Examine the hypothesis that the BMP receptors are over-expressed in metastatic prostate carcinoma. 2. Determine the function of endothelin-1 in molecular physiology of osteoblastic response to prostate cancer and translate findings to clinical data as a marker of therapeutic response. 3. Investigate the role of BPGF-1 in bone metastases and translate findings to clinical data set as a biomarker of therapeutic response and intervention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058236-04
Application #
5209250
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1996
Total Cost
Indirect Cost
Teply, Benjamin A; Wang, Hao; Luber, Brandon et al. (2018) Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol 19:76-86
Zennami, Kenji; Choi, Su Mi; Liao, Ross et al. (2018) PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance. Mol Cancer Res :
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Joshu, Corinne E; Peskoe, Sarah B; Heaphy, Christopher M et al. (2018) Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells. Prostate 78:233-238
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663
Shrestha, Eva; White, James R; Yu, Shu-Han et al. (2018) Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. J Urol 199:161-171
Lu, Yunqi; Hu, Zhongyi; Mangala, Lingegowda S et al. (2018) MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res 78:64-74
Das, Swadesh K; Pradhan, Anjan K; Bhoopathi, Praveen et al. (2018) The MDA-9/Syntenin/IGF1R/STAT3 Axis Directs Prostate Cancer Invasion. Cancer Res 78:2852-2863
Karnes, R Jeffrey; Choeurng, Voleak; Ross, Ashley E et al. (2018) Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol 73:168-175

Showing the most recent 10 out of 750 publications